Venture Kick is a private philanthropic initiative based in Zurich, Switzerland, founded in 2007 to support Swiss startups at the pre-seed stage. It provides up to 150,000 Swiss francs in funding and offers structured entrepreneurial training aimed at developing sustainable businesses. Entrepreneurs participate in a competitive process, pitching their ideas up to three times for increasing funding amounts, while receiving valuable feedback from expert juries. To date, Venture Kick has supported 600 startup projects with a total of 24.9 million francs, leading to the incorporation of 454 active companies that have created over 6,000 jobs and attracted approximately 2.49 billion francs in subsequent investments. Companies founded by Venture Kick alumni have notably achieved significant recognition, with 55 percent of the TOP 100 Swiss Startup Award in 2018 represented by these ventures. In 2019, the initiative aimed to allocate 4.35 million francs to support idea-stage projects, facilitating the transition of Swiss scientific innovations to global markets.
REMUUN is a biotechnology company focused on revolutionizing the development of therapeutic antibodies. It has created the MEGA platform, which mimics natural antibody gene modification and employs AID-based gene editing. This technology enables clients to accelerate, reduce costs, and enhance precision in the creation of monoclonal antibody therapies.
Scanvio
Grant in 2025
Scanvio offers AI-augmented ultrasound software for faster endometriosis diagnosis, providing expert sonography skills to gynecologists, improving health and surgical education.
BLEEDnFIRE Therapeutics
Grant in 2024
BLEEDnFIRE is a pioneering innovator in siRNA-based therapies for hemophilia. Its mission is to transform patient care and enhance the quality of life through targeted, effective, and novel treatments
Shape Biopharmaceuticals
Grant in 2024
Shape Biopharmaceuticals is dedicated to developing immunotherapeutic drugs aimed at treating chronic diseases that currently have limited treatment options. The company utilizes advanced protein design and formulation technologies to create a new generation of immunotherapies that address unmet medical needs. By focusing on genetically driven conditions, Shape Biopharmaceuticals seeks to enhance patient outcomes and provide hope for individuals who lack effective therapeutic alternatives.
Translation-X
Pre Seed Round in 2024
Translation-X is a biotechnology company specializing in the development of innovative therapeutics for Autism Spectrum Disorders (ASD). It employs a precision medicine strategy to target core symptoms of ASD, such as social interaction difficulties, aiming to provide effective treatment options for affected individuals.
Regenosca
Pre Seed Round in 2024
Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.
TrueYouOmics
Convertible Note in 2024
TrueYouOmics specializes in comprehensive blood testing services, leveraging multi-omics and artificial intelligence to identify disease risks and facilitate preventive health planning. The company's innovative approach involves analyzing an individual's DNA, RNA, and protein data, then integrating these insights with medical knowledge graphs to estimate personalized disease risks. This holistic health assessment empowers individuals to proactively manage their well-being by taking preventive measures.
Isospec Analytics
Pre Seed Round in 2024
Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.
Pace Locator
Grant in 2024
Pace Locator is a medical technology company that specializes in developing advanced imaging software. Its flagship product, also named Pace Locator, uses electrocardiogram (ECG) and echocardiogram (ECHO) data to generate 3D maps of the heart. This innovative tool helps healthcare professionals localize the source of cardiac arrhythmias and visualize the location of cardiac implantable electronic device (CIED) leads, enabling faster and more accurate diagnoses.
Procavea Biotech
Grant in 2023
Procavea Biotech specializes in developing a drug delivery platform centered on non-viral protein cages. This innovative platform is tailored for veterinary professionals, aiming to streamline and improve the efficiency of veterinary practice management. By providing a comprehensive solution, Procavea Biotech enhances overall operational effectiveness, enabling veterinary services to be delivered more seamlessly and integrated. Through its advancements, the company seeks to elevate the quality of care in veterinary practices.
Orio Therapeutics
Convertible Note in 2023
Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.
HeroSupport
Grant in 2023
HeroSupport is a medical device manufacturing company based in Veyrier, Geneva, established in 2019. The company specializes in creating personalized solutions that transform imaging and treatment tables into medical immobilization devices designed to enhance patient comfort during clinical procedures. By providing tailored support, these devices allow patients to receive prone breast radiotherapy without the need to adapt to the standard table setup. This innovation not only improves patient comfort but also aims to enhance the effectiveness and cost efficiency of cancer treatment for healthcare providers.
Orio Therapeutics
Convertible Note in 2023
Orio Therapeutics specializes in regenerative medicine and protein engineering. The company modifies therapeutic proteins to enhance their delivery and efficacy, focusing on controlled localization. This approach aims to improve patient outcomes, particularly for those with myocardial infarction, while potentially reducing dosage requirements.
Isospec Analytics
Grant in 2023
Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Ocumeda
Grant in 2022
Ocumeda is a telemedical network specializing in ophthalmology, providing accessible eye examinations through collaborations with opticians, retirement homes, and various companies. The company's services include remote assessments conducted by board-certified ophthalmologists, utilizing a secure cloud platform and advanced medical artificial intelligence to enhance the screening process. This approach aims to enable opticians and pharmacies to effectively detect blindness and prevent vision loss, ensuring that individuals receive timely and accurate eye care.
SightIn Health
Grant in 2022
SightIn Health is a Swiss company founded in 2021 that specializes in artificial intelligence-powered software for portable ultrasound devices. The firm has developed an imaging platform that enhances the functionality of ultrasound machines by providing automated quality assessments, probe guidance, and image analysis. This technology aims to reduce the skill barrier traditionally associated with ultrasound equipment, making it easier for healthcare providers to capture and interpret medical images. By improving the accuracy of medical diagnostics and prognostics, SightIn Health supports healthcare companies in delivering better patient care.
Maven Health
Non Equity Assistance in 2022
Maven Health is a health tech company that provides an end-to-end metabolic health solution designed for healthcare providers. It specializes in assessing individuals' metabolic health using saliva as the bio-fluid for metabolite measurements. These measurements are analyzed with advanced Nuclear Magnetic Resonance (NMR) spectrometers employing custom analytical methods. The system is designed to be minimally invasive and cost-effective, assisting healthcare professionals in identifying at-risk individuals who may not be recognized through traditional healthcare practices. The results are delivered through an intuitive data platform, facilitating better decision-making and patient care.
FimmCyte
Grant in 2022
FimmCyte is a biotechnology company focused on developing innovative disease-modifying treatments for fibro-inflammatory diseases, with an initial emphasis on endometriosis. The company aims to accelerate the journey toward effective cures by addressing significant healthcare needs and introducing novel solutions that enhance women's health. FimmCyte is dedicated to empowering women to take control of their health and tackle unmet medical needs associated with these conditions.
Isospec Analytics
Grant in 2022
Isospec Analytics SA is a life science company specializing in molecular identification. It simplifies the process of identifying molecules, particularly in the fields of glycomics and metabolomics, to facilitate disease biomarker discovery. This, in turn, aids in the development of safer nutritional and pharmaceutical products. The company offers services like biomarker discovery, product characterization, metabolite structural identification, and glycan sequencing to its clients.
OptimaRatio
Grant in 2022
OptimaRatio liberates chronic and rare disease patients from managing their complex health data.
Avelo
Grant in 2022
Avelo is a manufacturer of diagnostic equipment focused on infectious diseases. The company has developed a non-invasive breath aerosol testing system that allows for rapid detection of multiple lower respiratory tract infections. This innovative product enables primary care providers to conduct quick sample-to-answer tests, providing results within minutes through a streamlined three-step process. By facilitating early diagnosis, Avelo's technology aims to improve patient outcomes through timely antibiotic or antiviral treatment and efficient patient referrals. The company's mission centers on enhancing the speed and accuracy of infectious disease diagnoses to ultimately save lives.
NexMR
Grant in 2022
NexMR is a Swiss company focused on enhancing drug discovery processes through its nuclear magnetic resonance (NMR) platform. The company offers comprehensive solutions designed to optimize throughput and resource utilization within drug discovery pipelines. By utilizing a proprietary NMR technique, NexMR enables rapid screening of libraries containing thousands of molecules, significantly accelerating the drug design process. The integration of machine learning enhances data analysis, allowing for exploration of previously uncharted targets. Additionally, NexMR's technology aids in quality control and research, facilitating the assessment of chemical samples' content, purity, and molecular structure. This capability supports healthcare professionals in evaluating the potential of new compounds and improving experimental turnaround times.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Simulatory
Grant in 2022
Simulatory is a developer of a virtual simulator aimed at training surgeons in ultra-minimally invasive endoscopic techniques for spinal surgery. The simulator offers an intuitive workspace and a simulation guide that leverages machine learning and artificial intelligence, allowing surgeons to practice in a safe, data-driven environment. This innovative approach enhances surgical training by providing realistic scenarios that prepare surgeons for complex procedures, ultimately improving patient outcomes in spinal surgery.
NexMR
Grant in 2022
NexMR is a Swiss company focused on enhancing drug discovery processes through its nuclear magnetic resonance (NMR) platform. The company offers comprehensive solutions designed to optimize throughput and resource utilization within drug discovery pipelines. By utilizing a proprietary NMR technique, NexMR enables rapid screening of libraries containing thousands of molecules, significantly accelerating the drug design process. The integration of machine learning enhances data analysis, allowing for exploration of previously uncharted targets. Additionally, NexMR's technology aids in quality control and research, facilitating the assessment of chemical samples' content, purity, and molecular structure. This capability supports healthcare professionals in evaluating the potential of new compounds and improving experimental turnaround times.
Rhovica Neuroimaging
Grant in 2022
Rhovica Neuroimaging is a rapid and safe placement of an external ventricular drain (EVD) and is a lifesaving emergency procedure. EVDs are thin catheters, that are inserted into the brain cavities (ventricles) for fluid drainage to decrease intracranial pressure (ICP) and for measurement of ICP.
Adaptyv Bio
Pre Seed Round in 2022
Adaptyv Bio is focused on developing a protein engineering platform that leverages cell-free synthetic biology and high-throughput nanofluidics. The company’s technology aims to identify new antibodies for various diseases by bridging the gap between computational predictions and experimental validation. This innovative approach enhances the ability of healthcare providers to improve patient outcomes through more effective therapeutic options.
Adiposs
Seed Round in 2021
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.
Bottneuro
Grant in 2021
Bottneuro specializes in developing non-invasive therapies for patients with early to moderate-stage Alzheimer's Disease. The company utilizes its NENI technology platform to create stimulation protocols that employ electrical stimulation of neurons and glial cells in the brain. Additionally, Bottneuro's innovative brain therapy system incorporates plant-based components and features a 3D-printed cap designed for continuous monitoring and targeted delivery of active substances. This approach aims to address the specific needs of Alzheimer's patients, ultimately enhancing their quality of life and improving treatment outcomes.
InnoSpina
Grant in 2021
InnoSpina specializes in the design and development of innovative 3D printed implants and surgical guiding instruments aimed at treating chronic back pain efficiently. The company focuses on creating minimally invasive and motion-preserving technologies for spinal disorders. Its products are designed to empower spine surgeons and interventional pain management specialists by providing safe, intuitive instruments that facilitate accurate positioning of implants. This approach simplifies surgical procedures and significantly reduces operative time, allowing surgeons to address chronic back pain in less than 30 minutes.
Nemosia
Grant in 2021
Nemosia is a company focused on the development of positron emission tomography (PET) tracers designed to diagnose neurological disorders. By leveraging advanced technology, Nemosia creates tracers that facilitate the early identification of neurodegenerative diseases. Their products utilize PET imaging to visualize N-methyl-D-aspartate (NMDA) receptors in the brain, allowing for timely intervention and management of neurological conditions. This innovative approach aims to enhance diagnostic capabilities and improve patient outcomes in the field of neurology.
Resmonics
Grant in 2021
Resmonics, established in October 2020 as a spin-off from ETH Zürich and the University of St. Gallen, specializes in privacy-friendly acoustic artificial intelligence designed to analyze soundscapes in various environments. Its primary focus is on detecting symptoms of infectious lung diseases, particularly for chronic disease management and monitoring respiratory symptoms. The company's flagship product line, Quorum, integrates this AI technology with air quality sensors and noise analytics to foster healthy and productive working conditions. Additionally, Resmonics develops tools that provide objective, clinically validated insights into respiratory health, offering early warnings for potential crises and enhancing patient care through mobile applications.
Abologix
Debt Financing in 2021
Abologix is a biopharmaceutical company focused on developing innovative therapies for oncology. The company specializes in creating monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. This treatment aims to provide options for patients who do not respond to conventional cancer therapies, addressing various oncological conditions. By advancing its research in this area, Abologix seeks to enhance treatment outcomes and improve the quality of care for cancer patients.
CustomSurg
Grant in 2021
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
aiEndoscopic
Grant in 2021
aiEndoscopic is a MedTech start-up focused on enhancing the safety and simplicity of tracheal intubations through the integration of robotic endoscopy and artificial intelligence. The company designs intelligent medical equipment that combines visual access and precision to facilitate assistive and potentially autonomous endoscopy. This innovative approach aims to empower surgeons to perform intubations and other surgical procedures more effectively, ultimately reducing risks to patients' lives. With a commitment to improving surgical outcomes, aiEndoscopic strives to revolutionize the field of endoscopy by making advanced medical technology more accessible and user-friendly for healthcare professionals.
Regenosca
Pre Seed Round in 2020
Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.
4iLabs
Grant in 2020
4iLabs is developing a diagnostic toolbox to support clinicians in the therapy decision-making process for patients with progressed cancer beyond the standard of care.
CustomSurg
Convertible Note in 2020
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
Axentless
Grant in 2020
Axentless develops software using advanced algorithmic technologies to enable interactive speech therapy practice for stroke victims.
CustomSurg
Grant in 2020
CustomSurg specializes in the development of fracture-specific bone plates designed to address the complexities of joint-related bone fractures. By utilizing advanced technologies such as computer tomography and 3D printing, the company creates personalized implants that match the unique anatomy of each patient, enhancing surgical stability and efficiency. This innovative approach not only optimizes surgical planning but also aims to improve patient outcomes and reduce overall healthcare costs. CustomSurg's solutions target a significant market, potentially benefiting around 400,000 trauma patients annually. The involvement of a Harvard Medical School surgeon in the company’s medical oversight adds vital credibility to its offerings.
Abologix
Grant in 2020
Abologix is a biopharmaceutical company focused on developing innovative therapies for oncology. The company specializes in creating monoclonal antibodies that target the Junction Adhesion Molecule JAM-C and extracellular matrix-related proteins. This treatment aims to provide options for patients who do not respond to conventional cancer therapies, addressing various oncological conditions. By advancing its research in this area, Abologix seeks to enhance treatment outcomes and improve the quality of care for cancer patients.
Eldico Scientific
Seed Round in 2020
Eldico Scientific AG, founded in 2019 and based in Villigen, Switzerland, specializes in the development and manufacturing of electron diffractometers designed for the analysis of solid compounds. The company's innovative instruments enable researchers in various fields, including pharmaceuticals, agrochemicals, and advanced materials, to characterize nano-crystalline systems that were previously difficult to measure. By providing tools for nano-crystallographic investigations, Eldico aims to enhance the efficiency and cost-effectiveness of structural information gathering, thereby accelerating the drug discovery and development process. The company has made significant strides in the field, achieving proof of concept for its technology in collaboration with leading Swiss research institutions, and has received recognition for its contributions to scientific advancement.
Adiposs
Pre Seed Round in 2020
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.
Nutrix
Grant in 2020
Nutrix is a Swiss health-tech company founded in 2019 and based in Basel. It specializes in developing a nanosensor that is placed on the tooth to measure glucose levels in saliva, providing a non-invasive method for users to monitor their health. This technology is integrated with an external application that tracks food intake and offers dietary advice, aiming to aid in the prevention of diabetes. Nutrix combines artificial intelligence with wearables to create cost-effective healthcare solutions. In 2025, the company plans to introduce CortiSense, a non-invasive cortisol monitoring sensor that has already received a CES Innovation Award, further expanding its portfolio of health monitoring technologies. Through its innovative approach, Nutrix enables users to manage their health conditions effectively without the need for frequent medical consultations.
Flowbone
Grant in 2020
Flowbone is a company based in Lausanne, Switzerland, specializing in injectable biomaterials designed for the minimal-invasive augmentation of fragile bones that are at high risk of fracture. Its innovative technology stimulates the body's self-healing capabilities, allowing for local repair of bone and restoration of natural strength without compromising bone mechanics or blood flow. Flowbone focuses on addressing the needs of patients suffering from chronic insufficiency fractures and aims to enhance bone health, particularly in spine surgery. The company envisions a future where the elderly can maintain a high level of independence and quality of life, free from the debilitating effects of fragility fractures.
Regenosca
Grant in 2020
Regenosca SA is a Swiss company based in Lausanne that specializes in the development and commercialization of medical implants designed for bladder reconstruction. Founded in 2019, the company offers sterile, off-the-shelf implants that serve as alternatives to autologous tissue substitutes for soft tissue repair. These innovative biomaterials aim to enhance bladder preservation and minimize scarring, ultimately improving patients' quality of life. By focusing on easy-to-use medical devices, Regenosca is committed to advancing surgical practices and patient outcomes in bladder-related procedures.
MimiX Biotherapeutics
Grant in 2020
MimiX Biotherapeutics Sàrl, established in 2016 and based in La Tène, Switzerland, specializes in the development of biofabrication technology for therapeutic and diagnostic applications. The company focuses on creating an ultra-fast biomanufacturing process that enables the production of patient-specific biological tissue equivalents. This innovative approach supports regenerative medicine and personalized healthcare, allowing for tailored treatments that meet individual patient needs. By advancing tissue engineering techniques, MimiX Biotherapeutics aims to enhance the precision and effectiveness of medical interventions.
STIMIT
Pre Seed Round in 2020
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.
Genknowme
Pre Seed Round in 2020
GenKnowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By measuring DNA methylation biomarkers, the company provides insights into how diet, physical activity, tobacco use, and alcohol consumption influence individual health. GenKnowme aims to transform scientific research into practical applications, allowing health-conscious individuals to better understand their genetic predispositions and make informed lifestyle choices for proactive health management.
SurgeonsLab
Grant in 2020
SurgeonsLab, founded in 2020 and based in Bern, Switzerland, specializes in developing patient-specific training models for surgical procedures and the validation of new medical devices. The company focuses on microsurgical treatment planning and strategy, providing tools that enhance the training experience for medical professionals. By utilizing advanced technology, SurgeonsLab's products facilitate testing and planning for surgical interventions, significantly improving patient safety and outcomes. The company's innovative approach offers an alternative to traditional human and animal models, thereby enhancing the learning curve for medical trainees.
Selph
Grant in 2020
Selph is a medical technology company that focuses on developing a medical device that enables people to conduct a self-test for sexually transmitted diseases. It specializes in digital health, sensors, diagnostics, and medical services.
Inanna Fertility
Grant in 2020
Inanna Fertility specializes in developing clinical decision support solutions specifically for fertility clinics, focusing on enhancing the outcomes of in-vitro fertilization treatments. The company offers a groundbreaking algorithm-based platform that integrates machine learning and a comprehensive patient database to deliver personalized treatment recommendations. This platform is designed to dynamically adjust based on each patient's medical history and treatment responses, providing physicians with critical insights to inform their decisions. By leveraging this technology, Inanna Fertility aims to reduce the physical, emotional, and financial burdens faced by couples undergoing fertility treatments, ultimately improving their overall experience and success rates in achieving pregnancy.
Terapet
Grant in 2020
Terapet SA, founded in 2019 in Geneva, Switzerland, specializes in proton therapy, an advanced form of radiotherapy for cancer treatment. Established by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals, the company aims to provide precise tumor targeting while minimizing damage to adjacent healthy tissues. Terapet's innovative technology allows for a reduced radiation dose to surrounding healthy cells by administering high doses of protons that halt at specific depths within the patient. This capability enables medical professionals to monitor the proton dose in real-time and in three dimensions, making cancer treatment more effective and potentially more cost-efficient. The company has successfully demonstrated the feasibility of its concept and is in the process of developing an initial version for market launch.
Testmate Health
Grant in 2020
Testmate Health is a medtech startup and an award-winning spin-off of the University of Geneva, focused on developing innovative healthcare solutions. The company has created a smartphone-compatible test kit that can diagnose diseases with identifiable DNA or RNA sequences, providing results directly at home in just minutes. Its first product is a rapid urine self-test for the four most common sexually transmitted diseases, addressing the urgent need for timely diagnosis, as one million new STDs are diagnosed daily. Traditional testing often requires lab work and can take up to seven days for results. Testmate Health's all-in-one kit is designed for ease of use, allowing users to obtain immediate results that can be scanned by a smartphone for quick access to treatment if necessary. The company is also working on additional test kits for other diseases, aiming to empower individuals to manage their health conveniently from home.
Endotelix
Seed Round in 2020
Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.
Swiss Medical Union
Grant in 2020
Swiss Medical Union SA, founded in 2019 and based in Yverdon-les-Bains, Switzerland, specializes in healthcare technology focused on testing the interaction, efficiency, and safety of new medical products. The company manufactures Micro-Bioreactor equipment that allows for ex vivo testing with human organ and tissue models, enabling the selection of appropriate therapies tailored to individual patient needs. Additionally, Swiss Medical Union develops software that simulates organ activity, analyzes interactions between medical products and specific organs, and monitors real-time effects of treatments within the circulatory system. The company also provides clinical testing services aimed at supporting healthcare professionals in making informed clinical decisions, particularly in cancer treatment. Its offerings are designed to enhance therapeutic outcomes while minimizing the risks associated with unnecessary treatments.
MaxWell Biosystems
Grant in 2019
MaxWell Biosystems AG is an electronics and biotechnology company based in Zurich, Switzerland, dedicated to advancing neuroscience research and enhancing preclinical drug discovery. Founded in 2016, the company specializes in functional cell imaging platforms, most notably its MaxOne electrophysiology platform. This innovative system features a high-density microelectrode array with 26,400 electrodes and 1,024 low-noise readout channels, which allows for precise recording and stimulation of electrogenic cells in vitro. By enabling researchers to extract detailed single cell and network parameters, MaxWell's technology significantly accelerates the characterization of cellular functions, reducing the typical timeframe from several months to just a few weeks. This advancement aids in phenotypic screening as well as drug toxicity and efficacy testing.
anavo medical
Grant in 2019
Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.
Adiposs
Pre Seed Round in 2019
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.
Synendos Therapeutics
Pre Seed Round in 2019
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.
KaleiBox
Grant in 2019
KaleiBox is a Zurich-based company that specializes in the development of three-dimensional optical imaging devices tailored for small-animal imaging. The company offers two main products: a standalone-mode KaleiBox and a hybrid-mode KaleiBox. Both devices facilitate fluorescence tomography through a compact hardware design and advanced software, making them suitable for use in research laboratories, biotechnology industries, agricultural diagnostics, and image-guided surgeries. Drawing inspiration from the kaleidoscope, KaleiBox emphasizes versatility, portability, and aesthetic appeal, aiming to enhance the current workflow of three-dimensional fluorescence imaging, particularly in preclinical settings.
Eldico Scientific
Grant in 2019
Eldico Scientific AG, founded in 2019 and based in Villigen, Switzerland, specializes in the development and manufacturing of electron diffractometers designed for the analysis of solid compounds. The company's innovative instruments enable researchers in various fields, including pharmaceuticals, agrochemicals, and advanced materials, to characterize nano-crystalline systems that were previously difficult to measure. By providing tools for nano-crystallographic investigations, Eldico aims to enhance the efficiency and cost-effectiveness of structural information gathering, thereby accelerating the drug discovery and development process. The company has made significant strides in the field, achieving proof of concept for its technology in collaboration with leading Swiss research institutions, and has received recognition for its contributions to scientific advancement.
4i Labs
Grant in 2019
4i Labs generates multiplexed images of biological samples for molecular view of tumours.
OxyPrem
Pre Seed Round in 2019
OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.
OxyPrem
Seed Round in 2019
OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.
Microcaps
Pre Seed Round in 2019
Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.
Endotelix
Pre Seed Round in 2019
Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.
Alibion
Grant in 2019
Alibion AG, founded in 2018 and based in Allschwil, Switzerland, specializes in drug discovery and the development of therapeutics. The company addresses the challenge of bringing innovative therapies from academic laboratories to patients by accelerating early-stage development. Alibion focuses on identifying promising new therapeutics and collaborates with outsourced partners to streamline the development process, thereby minimizing time and costs while ensuring compliance with quality standards. By doing so, Alibion aims to enhance the availability of novel treatments, ultimately improving patient outcomes on a global scale.
Adiposs
Grant in 2019
Adiposs SA is a clinical-stage life science company focused on developing innovative medical imaging products aimed at the early detection of cachexia, a serious condition characterized by severe body wasting. The company has created a first-in-class CT contrast product that allows for the detection of body wasting prior to noticeable weight loss, potentially up to a year earlier. This advancement enables healthcare providers to identify cancer at an earlier stage, ultimately improving patient outcomes and enhancing their quality of life. By facilitating timely intervention, Adiposs aims to provide patients with a better chance of survival against cancer and other chronic illnesses.
anavo medical
Grant in 2019
Anavo Medical specializes in developing nanoparticle-based pharmaceutical products aimed at enhancing wound healing and minimizing complications associated with skin grafts. The company's innovative formulation utilizes bioactive nanoparticles suspended in a user-friendly matrix, incorporating active ingredients such as metal oxide nanoparticles. These components possess anti-inflammatory and neo-angiogenic properties, which stimulate blood vessel regeneration and mitigate inflammation. By leveraging advanced nanotechnology, Anavo Medical's products empower healthcare professionals to improve patient outcomes, ensuring safer surgeries and promoting faster recovery for individuals undergoing skin transplantation procedures.
STIMIT
Grant in 2019
STIMIT AG is a medtech company based in Nidau, Switzerland, established in 2018. The company focuses on developing therapies and medical devices aimed at patients who have lost their natural breathing function, particularly those on mechanical ventilation. A significant portion of time in intensive care is dedicated to weaning patients off ventilators and restoring diaphragm function, which is critical for independent breathing. STIMIT's technology non-invasively activates the diaphragm, helping to keep it strong and functional, ultimately aiming to liberate patients from ventilators and reduce associated morbidity and mortality. Additionally, STIMIT is advancing a proprietary method for localized delivery of cancer immunotherapy, enhancing the efficacy and safety of treatment for patients with solid tumors. This dual focus positions STIMIT at the forefront of innovation in both respiratory care and oncology.
Synendos Therapeutics
Pre Seed Round in 2019
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.
Genknowme
Grant in 2019
GenKnowme S.A. is a life science company based in Lausanne, Switzerland, founded in 2019. It specializes in epigenetic testing that assesses the impact of lifestyle and environmental factors on biological age. By measuring DNA methylation biomarkers, the company provides insights into how diet, physical activity, tobacco use, and alcohol consumption influence individual health. GenKnowme aims to transform scientific research into practical applications, allowing health-conscious individuals to better understand their genetic predispositions and make informed lifestyle choices for proactive health management.
Endotelix
Grant in 2019
Endotelix is a Swiss biotech start-up and a spin-off from the University of Geneva, focused on developing innovative solutions for Antiphospholipid Syndrome. The company specializes in creating fast, sensitive, and reliable diagnostic tests and treatment options aimed at detecting circulating antibodies associated with this condition. Endotelix primarily targets the healthcare needs of pregnant women and adolescent children, providing research tools and therapies that assist healthcare professionals in reducing pregnancy-related complications and enhancing overall healthcare outcomes.
Hi-D Imaging
Grant in 2019
Hi-D Imaging AG, founded in 2019 and based in Winterthur, Switzerland, specializes in a SaaS-based pre-operational planning platform tailored for cardiac procedures, particularly trans-catheter aortic valve implantation. The platform assesses the hemodynamics of patient-specific anatomies, allowing physicians to analyze blood flow patterns and perform in-vitro fluid dynamic analyses. This technology enables the selection of the optimal size and shape of heart valves, facilitating personalized solutions for patients with aortic stenosis before cardiac surgery. By streamlining pre-operational planning and enhancing data-driven decision-making, Hi-D Imaging aims to improve outcomes for patients with cardiovascular diseases while reducing the need for unnecessary medical imaging examinations. The company's AI-based cardiac image processing technology further supports medical professionals by producing detailed images of cardiac structures, thereby decreasing planning times and addressing the limitations of traditional medical scans.
B-rayZ
Grant in 2019
B-rayZ is a spin-off from the University Hospital Zurich, focused on enhancing radiology through advanced technology. The team comprises experienced radiologists, data scientists, and physicians with over 15 years of expertise in medical imaging. B-rayZ develops artificial intelligence-based software that aids radiologists in mammography by offering real-time assessments of image quality and breast density. This innovative software enables accurate and standardized evaluations of medical imaging data, thereby improving breast cancer detectability. By providing intelligent tools, B-rayZ supports radiologists in enhancing their diagnostic capabilities while also contributing to reduced healthcare costs.
Synendos Therapeutics
Grant in 2018
Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. The company focuses on developing innovative therapies for unmet needs in neuropsychiatric disorders, particularly anxiety, mood, and stress-related conditions. Synendos utilizes a novel drug target within the endocannabinoid system to restore the brain's natural functioning. Its therapies involve the modulation of cannabinoid activity and the inhibition of endocannabinoid transport across cell membranes, addressing altered neurotransmission in various brain regions. This approach presents a promising solution to the significant demand for effective pharmacological treatments, especially for conditions like post-traumatic stress disorder (PTSD), which currently lacks adequate therapeutic options.
OxyPrem
Grant in 2018
OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.
Microcaps
Grant in 2018
Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.
Aspivix
Seed Round in 2018
Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.
SEED Biosciences
Pre Seed Round in 2018
SEED Biosciences SA is a Swiss biotechnology company founded in 2018 and headquartered in Renens, Switzerland. The company specializes in developing innovative solutions for single-cell assays, most notably its product DispenCell, a compact pipetting robot designed to facilitate the precise isolation of single cells. This technology is essential for various biological applications, including the production of biologics, cancer diagnostics, stem cell therapies, and personalized medicine. By enabling efficient single-cell isolation, SEED Biosciences aims to advance research and clinical practices in the life sciences sector.
MOMM Diagnostics
Grant in 2018
MOMM Diagnostics is a Swiss company founded in 2018 and headquartered in Basel. It specializes in the development of an in-vitro diagnostic test aimed at the early diagnosis of preeclampsia, a serious condition that can affect pregnant women. The company's innovative diagnostic device is designed for use at the point of care, allowing for quicker diagnosis and intervention, thereby improving patient outcomes. By focusing on women's health, MOMM Diagnostics aims to provide essential support to healthcare providers and enhance the care of pregnant women experiencing potential complications.
ONtrack Diagnostics
Grant in 2018
ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in the development of non-invasive assays aimed at the screening, diagnosis, and monitoring of cancer. The company's initial product is a urine assay designed specifically for the screening of prostate cancer, reflecting its commitment to advancing cancer detection methods. Through its innovative approaches, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.
EBAMed
Seed Round in 2018
EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.
OxyPrem
Grant in 2018
OxyPrem AG is a Swiss company that specializes in developing and manufacturing sensor solutions for monitoring preterm infants. Founded in 2018 and based in Zurich, OxyPrem offers an advanced reusable oxygen sensor that continuously measures brain oxygen levels in high-risk preterm infants using noninvasive near-infrared light technology. This device accurately determines hemoglobin oxygen saturation in any human tissue, allowing healthcare providers to deliver improved clinical care while significantly reducing waste. By enabling real-time monitoring, OxyPrem's technology plays a crucial role in preventing early death and mitigating the risk of severe long-term brain damage in this vulnerable population.
Volumina Medical
Pre Seed Round in 2018
Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.
Clemedi
Grant in 2018
Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.
Microcaps
Grant in 2018
Microcaps AG is a company based in Zurich, Switzerland, specializing in the development of innovative microencapsulation technology. Founded in 2018, it focuses on creating a scalable production system for precise microcapsules and microparticles using advanced microfluidics. The company's devices enable the fabrication of monodisperse capsules and emulsions of various sizes, providing tailored solutions for drug delivery, probiotic encapsulation, and enhancing the stability of pharmaceutical agents and fragrances in cosmetic products. Microcaps aims to offer a fully automated encapsulation micro-factory that ensures size control and precise dosing, significantly improving production efficiency and throughput rates compared to conventional methods.
Qnami
Seed Round in 2018
Qnami AG is a Swiss company established in 2017, specializing in the development of quantum sensing technologies for nanoscale imaging. The company manufactures non-invasive sensors, including the ProteusQ magnetic imaging microscope and the Quantum Diamond product line, which features diamond probes with single nitrogen-vacancy (NV) centers for high-resolution magnetic imaging. These advanced technologies enable the measurement of electric and magnetic fields with exceptional sensitivity, facilitating a range of applications such as the characterization of magnetic random-access memory (MRAM), imaging of proteins, and fundamental studies of superconductors. Qnami's innovations unlock new possibilities in both scientific research and industrial applications, aiming to enhance understanding and improve various aspects of life and technology.
DocsVisit
Grant in 2018
DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. The platform utilizes machine learning, artificial intelligence, and search algorithms to identify available caregivers in specific regions, allowing patients to easily find and book appointments with doctors and physicians who offer private care services in their homes. This service aims to streamline the process of accessing healthcare while ensuring patients receive the medical attention they need in the comfort of their own environment.
SEED Biosciences
Grant in 2018
SEED Biosciences SA is a Swiss biotechnology company founded in 2018 and headquartered in Renens, Switzerland. The company specializes in developing innovative solutions for single-cell assays, most notably its product DispenCell, a compact pipetting robot designed to facilitate the precise isolation of single cells. This technology is essential for various biological applications, including the production of biologics, cancer diagnostics, stem cell therapies, and personalized medicine. By enabling efficient single-cell isolation, SEED Biosciences aims to advance research and clinical practices in the life sciences sector.
ONtrack Diagnostics
Grant in 2018
ONtrack Diagnostics is a medical technology company based in Zurich, Switzerland, that specializes in the development of non-invasive assays aimed at the screening, diagnosis, and monitoring of cancer. The company's initial product is a urine assay designed specifically for the screening of prostate cancer, reflecting its commitment to advancing cancer detection methods. Through its innovative approaches, ONtrack Diagnostics seeks to improve patient outcomes in the field of oncology.
Aspivix
Grant in 2018
Aspivix SA is a Swiss company specializing in the development of innovative medical devices aimed at enhancing gynecological procedures. Founded in 2015 and headquartered in Lausanne, Aspivix focuses on creating minimally invasive surgical instruments that prioritize patient comfort and safety. Its flagship product, CAREVIX, utilizes a patented suction technology to stabilize the cervix during procedures, effectively reducing pain and minimizing the risk of bleeding, lesions, and infections. This approach replaces traditional methods, such as the use of forceps, offering a gentler alternative for both women and gynecologists. Through its advancements, Aspivix aims to transform the landscape of gynecological care by making procedures safer and more efficient.
Mirrakoi
Pre Seed Round in 2018
Mirrakoi SA is a Swiss company established in 2018 and is a spin-off from the Swiss Federal Institute of Technology in Lausanne. It specializes in developing computer-aided design software, particularly focused on the medical field. The company's flagship product, Rhino3DMedical, facilitates a seamless workflow that allows users to view, analyze, and segment medical images, ultimately enabling the creation of 3D-printable meshes and CAD models from CT and MRI scans. This proprietary software is designed with a user-friendly interface, making it accessible for orthopedic surgical planning and the production of patient-specific anatomical models. Mirrakoi's innovative technology streamlines the process of generating anatomical 3D prints, enhancing both efficiency and precision in medical applications.
EBAMed
Grant in 2018
EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.
Volumina Medical
Grant in 2018
Volumina Medical SA is a Swiss company specializing in the development, manufacturing, and commercialization of tissue reconstruction technologies for the reconstructive and plastic surgery markets. It focuses on tissue engineering and has created injectable 3D scaffolds designed to reconstruct soft tissue volumes lost due to tumor ablation, disease, trauma, or for aesthetic reasons. These innovative scaffolds can be injected through thin cannulas, which helps to minimize both intervention and recovery times for patients. Volumina Medical aims to address the challenges associated with the natural repair of soft tissues, offering solutions that enhance surgical outcomes.
Clemedi
Grant in 2018
Clemedi AG develops innovative diagnostic workflows for infectious diseases, focusing on in vitro diagnostic tests that leverage next-generation sequencing and machine learning technologies. Established in 2018 and headquartered in Schlieren, Switzerland, the company aims to combat antibiotic resistance, which is projected to cause 10 million deaths annually by 2050. Clemedi's test kits are designed to diagnose drug-resistant infections directly from patient samples within a day, thereby enhancing doctors' decision-making and facilitating timely, personalized antibiotic therapies. By providing comprehensive information for targeted treatment, Clemedi strives to reduce antibiotic consumption and slow the spread of resistance, ultimately benefiting patients suffering from infectious diseases.
DocsVisit
Grant in 2018
DocsVisit is a healthcare management platform that facilitates connections between patients and medical practitioners for home visits. The platform utilizes machine learning, artificial intelligence, and search algorithms to identify available caregivers in specific regions, allowing patients to easily find and book appointments with doctors and physicians who offer private care services in their homes. This service aims to streamline the process of accessing healthcare while ensuring patients receive the medical attention they need in the comfort of their own environment.
MotionTech
Grant in 2018
MotionTech is a company that has developed innovative silicone 3D printing technology aimed at transforming the orthopaedic industry. The company offers a service called "Your Liner," which enables prosthetic technicians worldwide to order customized silicone equipment tailored to individual patient needs. This approach fosters a shift from traditional mass production to mass customization in orthopaedic solutions. MotionTech's technology includes a 3D scanner that accurately captures the shape of a patient's stump, allowing for precise measurements and modifications. These specifications are then used to produce custom-made silicone sleeves that help redistribute pressure and reduce friction, addressing common issues of prosthetic discomfort. Through these advancements, MotionTech aims to enhance the overall experience for both prosthetists and patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.